Insulet Corp.

PODD | NASDAQ

Price Alert Chart Builder DCF Calculator

$152.35

+$2.67 (+1.78%)

Nov 2, 2026, 12:15 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.78%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

84.9

-1.0 pts

Fundamentals Excellent

Market Sentiment Bullish

Moat Narrow

Sector Rank #6/1028 (Top 1%)

Full Analysis

Key Statistics

Market Data

Market Cap $10.57B

1D Range

149.68 154.54

52W Range

130.47 346.36

Valuation (TTM)

PE 27.98

PB 7.30

EV/EBITDA 16.95

Valuation (NTM)

Forward PE 18.55

Forward PEG 0.84

Price Target $180.59

Cash Flow

FCF Yield 2.9%

SBC Adj. FCF Yield 2.1%

SBC Impact -26.1%

Margins

Gross Margin 71.1%

Operating Margin 16.9%

FCF Margin 9.8%

Growth (CAGR)

Revenue 3Y | 5Y 27.7% | 25.1%

Dil EPS 3Y | 5Y 81.2% | 38.9%

FCF 3Y | 5Y 15.0% | 88.6%

Returns

ROA 11.9%

ROE 26.7%

ROIC 16.0%

Financial Health

Net Debt

$413.5M

Current Ratio 2.48

Interest Coverage 8.14

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform ...

Sector Healthcare

Industry Medical - Devices

Employees 5,400

IPO Date May 15, 2007

Website www.insulet.com

Fiscal Year January - December

Full Company Profile

Latest News

5 days ago · zacks.com

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 days ago · globenewswire.com

Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

17 days ago · zacks.com

Here's Why Insulet (PODD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

21 days ago · businesswire.com

Insulet Announces Omnipod Discover Now Available in U.S.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of.

1 month ago · businesswire.com

Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the.

1 month ago · zacks.com

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 month ago · marketbeat.com

Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum

Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.

1 month ago · seekingalpha.com

Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

2 months ago · businesswire.com

Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About.